Direct-compression blends of praziquantel premix for companion-animal tablets are specified with particle-size overlap between API and excipient fractions. Praziquantel crystals are air-jet milled to a D90 below 10 µm before blending with lactose monohydrate and microcrystalline cellulose, because dissolution rate in 0.1 M HCl at 37°C is surface-area limited. The milled API is characterized by laser diffraction per ISO 13320 and by bulk density analysis before scale-up; batches with a bulk density above 0.45 g/cm³ may require lower press speed or forced feeder adjustment. A 50 mg tablet formula with API content of 25% w/w requires geometric pre-blending of API with hydrophilic fumed silica at a 1:3 ratio for 10 min in a bin blender at 12 rpm; the resulting premix is then added to the main blend. If the angle of repose exceeds 35° or segregation is detected by stratified sampling, the process switches to wet granulation with starch paste, but water addition is limited to 6–8% because excessive moisture can compact praziquantel fines. The final blend is sampled and tested using high-performance liquid chromatography for uniformity of content, with acceptance range 90.0–110.0% label claim and relative standard deviation below 5.0%. Compression is performed on an instrumented rotary tablet press with pre-compression force 5–8 kN and main compression force 12–18 kN; tablet crushing strength is monitored at 60–120 N and friability is kept below 1.0% per Ph. Eur. 2.9.7. Uniformity of mass is tested per Ph. Eur. 2.9.5. The bitter taste of praziquantel necessitates a film coating of hydroxypropyl methylcellulose and polyethylene glycol applied in a perforated pan coater to a weight gain of 2.0–3.5%. Finished tablets are tested against USP <711> dissolution in 0.1 M HCl with sodium lauryl sulfate, using Apparatus 2 at 50 rpm; acceptance criterion Q = 80% dissolved in 30 min is common but must be justified against the reference listed product in the target jurisdiction. A desiccant is included in HDPE bottle packs because praziquantel tablets stored at 40°C/75% RH can display moisture-induced surface dulling and hardness drift if coating integrity is compromised.

What limits aqueous solubility in praziquantel oral solutions and drenches?

Praziquantel displays pH-independent solubility below 0.5 mg/mL in purified water at 25°C; this creates precipitation risk when a non-aqueous concentrate is diluted into aqueous media or rumen fluid. Oral solution development relies on co-solvent systems containing propylene glycol, ethanol, or benzyl alcohol at mass fractions above 40%, with polysorbate 80 or macrogol 15 hydroxystearate as wetting agents. The solution is filled into HDPE dosing bottles with a calibrated oral dosing gun; delivered volume is checked by weight at 20°C because viscosity varies with temperature. The formulation is filtered through a 5 µm membrane before filling to remove undissolved nuclei. Stability protocols follow ICH Q1A; samples are stored at 5°C, 25°C/60% RH, and 40°C/75% RH, with assay, pH, visual precipitation, and particulate matter per Ph. Eur. 2.9.19. For sheep drench applications, the dose is set by bodyweight and is commonly delivered at 3.75–5.0 mg/kg as a single oral dose; the final product must meet regional residue and withdrawal requirements. Where a dry powder for oral solution is required, praziquantel is dry-blended with dextrose, citric acid, and sodium bicarbonate in a low-humidity suite; sachet fill weight is controlled to ±2.0% and moisture is kept below 2.0% by Karl Fischer testing. Reconstitution with potable water to a final concentration of 5 mg/mL must produce a clear solution after stirring for 60 s at 20°C; if cloudiness persists, the co-solvent ratio is adjusted during preformulation. The bitter taste is controlled by adding sucralose or thaumatin at 0.1–0.3% and buffering the vehicle to pH 4.5–5.5; above pH 6.5 the praziquantel base can precipitate from supersaturated co-solvent systems on dilution. Published data for exact dilution ratios in ruminal fluid is limited, so a dilution compatibility test in simulated gastric fluid and artificial rumen medium is requested before commercial release.

For intramuscular or subcutaneous administration, praziquantel is commonly formulated as a sterile solution in a mixture of benzyl alcohol, propylene glycol, and polyethylene glycol 400; praziquantel concentration is often specified at 56.8 mg/mL in commercialized companion-animal presentations. The non-aqueous vehicle requires moisture control because water content above 0.5% can reduce dielectric stability and may promote hydrolysis of praziquantel during terminal sterilization. The solution is compounded in a closed stainless-steel vessel under nitrogen, then passed through a 0.22 µm sterilizing-grade polyvinylidene fluoride filter. Terminal sterilization by autoclaving at 121°C for 15 min may degrade praziquantel in aqueous environments, so aseptic filtration is preferred when solubility permits; if terminal sterilization is used, the thermal cycle must be validated by recovery of praziquantel with assay loss not more than 2.0%. Filling is performed in an ISO 14644-1 class 7 background with class 5 critical zone. The filled vials are tested for sterility according to Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins according to Ph. Eur. 2.6.14, and particulate matter per USP <788>. Aluminum caps and bromobutyl rubber stoppers are selected to avoid zinc leaching. Residual solvent levels are checked against VICH GL18 (ICH Q3C) for benzyl alcohol and polyethylene glycol impurities. User safety requires a withdrawal interval label; for production-scale filling of non-aqueous injectables, peristaltic pumps with silicone tubing are replaced by ceramic rotary piston pumps to avoid extractables. The viscosity of the vehicle at filling temperature 20–25°C is maintained below 80 mPa·s to ensure fill weight uniformity below ±1.0%.

In equine anthelmintic programs, praziquantel oral paste must remain physically stable across the temperature range encountered in barn storage while also extruding from a multi-dose syringe with acceptable force. The vehicle is typically a thickened non-aqueous gel composed of medium-chain triglycerides, hydrogenated castor oil, and colloidal silica; praziquantel is dispersed at 7.5–15% w/w after air-jet milling to a D90 below 10 µm. The paste is mixed under vacuum in a planetary mixer to reduce air entrapment, then filled into graduated dosing syringes. Syringe fill weight is verified at ±1.5% of target; expulsion force is measured by texture analyzer with a 10–30 N plateau as the acceptance range. Sedimentation studies are run at 4°C, 25°C, and 40°C for 90 days; the top, middle, and bottom segments must assay within 90–110% of label claim. The dose is delivered by bodyweight graduation; published equine dose ranges for cestode control are generally 1.0–2.5 mg/kg depending on the combination with ivermectin or moxidectin. Because praziquantel is bitter, the paste often includes apple flavor and saccharin sodium; palatability trials record acceptance within 5 min but remain a behavioral variable. Stability data support storage below 30°C; freezing below 0°C can stiffen the paste and increase expulsion force beyond the syringe limit.

Feed premix homogeneity and medicated feed carry-over thresholds

Veterinary-grade praziquantel premix for feed incorporation is manufactured by stepwise dilution to overcome the cohesive nature of micronized API. A 1% or 5% praziquantel premix is built on a carrier system of calcium carbonate, wheat middlings, or lactose monohydrate; the API is first mixed with colloidal silica at 2% of the premix mass for 10 min in a high-shear mixer to de-agglomerate. The intermediate blend is then diluted into a double-ribbon blender with a working capacity of 60–70% of total volume and mixed for 15–20 min at 20–30 rpm; prolonged mixing beyond 30 min can increase electrostatic adhesion to the vessel wall and lower assay in sampled portions. Homogeneity is assessed by taking 10 samples from different geometric positions and measuring praziquantel content by HPLC; a relative standard deviation below 5.0% is required by most compendial and regulatory expectations. Carry-over in the feed mill is controlled by sequencing the praziquantel batch after a flushing batch of ground corn; residual praziquantel in the next non-medicated feed is monitored and should remain below 1% of the intended medicated dose, consistent with EU Regulation 2019/4 risk-based limits. The premix must comply with current Good Manufacturing Practice under 21 CFR Part 225 and Part 226 in US applications; feed mills are expected to maintain master formulas and production records. The premix must be labeled with the species and withdrawal period; for swine and aquaculture approvals, regional monographs vary. The table below aligns the production checkpoints with pharmacopoeial and feed-safety methods.

When praziquantel granules are applied as top-dress medication

Granulation to a dustless top-dress particle is required when the premix must remain free-flowing at the feed bunk and mask the bitter praziquantel taste. A wet granulation route is performed with purified water or a low-viscosity povidone binder solution; the binder level is held at 2.5–4.0% dry mass. The wet mass is extruded through a dome granulator with a 0.8 mm screen and spheronized at 800–1000 rpm until spheroid particles in the 500–850 µm range are produced. Drying in a fluid-bed dryer at inlet air temperature 55–65°C proceeds until loss on drying is below 2.0%; higher temperatures above 70°C risk solid-state changes or surface pitting. The dried granules are coated with a taste-masking layer of ethylcellulose or methacrylic acid copolymer in a Wurster column, with a weight gain of 5–8%. The coating efficiency is checked by dissolution testing in phosphate buffer pH 6.8 over 60 min; release is expected to be immediate after the polymer film ruptures, but published data for praziquantel granule dissolution in simulated swine gastric fluid is limited. The finished granules are filled into laminated aluminum pouches with desiccant to keep moisture below 3.0% during shelf life. For top-dress application, the granules are mixed with a small amount of feed immediately before administration; this avoids segregation in the feed bunk and reduces variability in intake.

Because capsule filling demands a free-flowing, dense powder, praziquantel is dry-granulated with lactose monohydrate and crospovidone before encapsulation into hard gelatin or hydroxypropyl methylcellulose capsules. The API is first slugged on a rotary tablet press, then passed through a 1.0 mm oscillating granulator and lubricated with sodium stearyl fumarate at 1.0% w/w. Powder fill weight is controlled on a dosator-type capsule machine; for a 25 mg capsule with a fill weight of 200 mg, the target fill weight tolerance is ±3.0%. Content uniformity is tested according to USP <905> or Ph. Eur. 2.9.40 with acceptance value ≤ 15. The dissolution test uses USP Apparatus 1 at 100 rpm in 900 mL of 0.1 M HCl containing 0.2% sodium lauryl sulfate; the Q value is set at 80% in 30 min. Hard gelatin capsule shell moisture is maintained at 13–16% before filling; HPMC capsules are selected when fill water activity exceeds 0.6 to avoid shell softening and dimensional change. The filled capsules are packed in cold-form aluminum blisters with desiccant; storage at 25°C/60% RH is monitored for assay, dissolution, and water content over 24 months. If encapsulated praziquantel is intended for equine use, the dose may require multiple capsules per treatment, which is a compliance limitation; published data for field acceptance in horses is limited.